Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 5:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,388 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Peripheral Blood Stem Cell Transplant Clear all
Not listed Phase 1 Interventional

Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00009750
View directory record Official record
Conditions
Prostate Cancer
Interventions
filgrastim, monoclonal antibody m170, cyclosporine, paclitaxel, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody m170, yttrium Y 90 monoclonal antibody m170
Biological · Drug · Procedure + 1 more
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 6, 2026, 5:09 AM EDT
Completed No phase listed Observational

Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant

NCT00510315
View directory record Official record
Conditions
Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome
Interventions
Questionnaires, Laboratory tests, Abdominal MRI
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Oct 6, 2026, 5:09 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

TMLI and Alemtuzumab for Treatment of Sickle Cell Disease

NCT05384756
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Alemtuzumab, Hematopoietic Cell Transplantation, Intensity-Modulated Radiation Therapy, Sirolimus
Drug · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 6, 2026, 5:09 AM EDT
Completed Phase 1 Interventional

Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

NCT00641381
View directory record Official record
Conditions
Lymphoma
Interventions
carmustine, cyclophosphamide, etoposide, pharmacological study, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Drug · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
10 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 6, 2026, 5:09 AM EDT
Completed Phase 1 Interventional

Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission

NCT00002977
View directory record Official record
Conditions
Ovarian Cancer
Interventions
filgrastim, melphalan, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 15, 2010 · Synced Oct 6, 2026, 5:09 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA

NCT00455312
View directory record Official record
Conditions
Dyskeratosis Congenita, Aplastic Anemia
Interventions
Campath 1H, Cyclophosphamide, Fludarabine, Total Body Irradiation, Stem Cell Transplantation, antithymocyte globulin, Methylprednisolone
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 6, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma

NCT00439465
View directory record Official record
Conditions
Myeloma, Transplant-eligible Patients
Interventions
Ex-vivo expanded effector cells
Biological
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 6, 2026, 5:09 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease

NCT00054600
View directory record Official record
Conditions
Graft-versus-Host Disease
Interventions
Methoxsalen, Extracorporeal Photopheresis
Drug · Procedure
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
6
States / cities
Gainesville, Florida • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Oct 6, 2026, 5:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

NCT01921387
View directory record Official record
Conditions
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8
Procedure · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Oct 6, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma

NCT00006184
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Myeloma Immunoglobulin Idiotype Vaccine, Bortezomib, Cyclophosphamide, Cyclosporine, Doxorubicin hydrochloride, Etoposide, Fludarabine phosphate, Prednisone, Vincristine Sulfate, Methotrexate, GMCSF (granulocyte macrophage colony stimulating factor), GCSF (granulocyte colony stimulating factor)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 6, 2026, 5:09 AM EDT
Completed No phase listed Observational

Analysis of T Cell and Natural Killer (NK) Cell in Relation to Viral Infections in Pediatric Stem Cell Transplant Patients and Donors

NCT02301065
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 6, 2026, 5:09 AM EDT
Completed Phase 1Phase 2 Interventional

Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Ewing's Sarcoma or Rhabdomyosarcoma That Has Spread to the Bone

NCT00006234
View directory record Official record
Conditions
Metastatic Cancer, Sarcoma
Interventions
peripheral blood stem cell transplantation, holmium Ho 166 DOTMP
Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 1, 2011 · Synced Oct 6, 2026, 5:09 AM EDT
Completed Phase 2 Interventional

Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00007852
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, carmustine, cytarabine, etoposide, melphalan, autologous hematopoietic stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 6, 2026, 5:09 AM EDT
Terminated Phase 1 Interventional

Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy

NCT00629187
View directory record Official record
Conditions
Central Nervous System Neoplasms, Neoplasm Metastasis
Interventions
Temozolomide
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 6, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

NCT00003042
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, cisplatin, cyclophosphamide, doxorubicin hydrochloride, melphalan, mesna, paclitaxel, tamoxifen citrate, bone marrow ablation with stem cell support, conventional surgery, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2025
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 6, 2026, 5:09 AM EDT
Recruiting Phase 3 Interventional

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

NCT06022939
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bortezomib, Computed Tomography, Cyclophosphamide, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Echocardiography, Magnetic Resonance Imaging, Melphalan, Positron Emission Tomography, Stem Cell Isolation, Survey Administration
Procedure · Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
117
States / cities
Goodyear, Arizona • Tucson, Arizona • Duarte, California + 93 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 6, 2026, 5:09 AM EDT
Completed Phase 1 Interventional

Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia

NCT01020539
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Juvenile Myelomonocytic Leukemia
Interventions
Fludarabine, Busulfan, GVHD Prophylaxis, Gemtuzumab Ozogamicin, Anti-Thymocyte Globulin, Isotretinoin
Drug
Lead sponsor
Columbia University
Other
Eligibility
1 Month to 30 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 6, 2026, 5:09 AM EDT
Completed Phase 2 Interventional

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer

NCT00053196
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myeloproliferative Neoplasms
Interventions
anti-thymocyte globulin, G-CSF, busulfan, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus, allogeneic cell transplantation, allopurinol
Biological · Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Up to 69 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
12
States / cities
La Jolla, California • Lewes, Delaware • Newark, Delaware + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2016 · Synced Oct 6, 2026, 5:09 AM EDT
Completed Phase 3 Interventional

High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

NCT00002945
View directory record Official record
Conditions
Leukemia
Interventions
aldesleukin, filgrastim, cyclophosphamide, cytarabine, etoposide, idarubicin, melphalan, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
25 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2012 · Synced Oct 6, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant

NCT01927731
View directory record Official record
Conditions
Bone Marrow Transplantation Recipient, Cord Blood Transplant Recipient, Hematopoietic Cell Transplantation Recipient
Interventions
Eltrombopag Olamine, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 6, 2026, 5:09 AM EDT
Completed Phase 1 Interventional

Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

NCT00301951
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, sargramostim, busulfan, fludarabine phosphate, mycophenolate mofetil, tacrolimus, umbilical cord blood transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Oct 6, 2026, 5:09 AM EDT
Terminated Phase 2 Interventional Results available

Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies

NCT03717480
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
ClinicMACs
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 6, 2026, 5:09 AM EDT
Terminated Phase 3 Interventional Results available

Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib

NCT02489500
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Bortezomib, Melphalan, Neupogen, Stem Cell Collection, Stem cell infusion
Drug · Procedure
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 6, 2026, 5:09 AM EDT
Terminated Phase 2 Interventional Results available

Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim

NCT01182675
View directory record Official record
Conditions
Severe Combined Immunodeficiency
Interventions
Transplant Conditioning with Mobilization Only, Transplant Conditioning with Mobilization and Alemtuzumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 3 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 6, 2026, 5:09 AM EDT